Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.46 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10356667 | 0.87 | PRSS1 (0.56) | SMN1; SMN2ALDH1A1MAPK1HSD17B10NPC1 | |
| SCHEMBL10423618 | 0.86 | PRSS1 (0.57) | SMN1; SMN2ALDH1A1MAPK1NPC1RAB9A | |
| SCHEMBL6018274 | 0.86 | PRSS1 (0.57) | SMN1; SMN2ALDH1A1MAPK1NPC1RAB9A | |
| SCHEMBL82488 | 0.84 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1MAPK1RAB9AL3MBTL1 | |
| SCHEMBL1803092 | 0.84 | ADRA2A (0.53) | SMN1; SMN2ALDH1A1MAPK1HSD17B10NPC1 | |
| SCHEMBL30969316 | 0.83 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1MAPK1HSD17B10NPC1 | |
| SCHEMBL960116 | 0.83 | CYP3A4 (0.52) | ALDH1A1L3MBTL1KDM4EPOLBHDAC3 | |
| SCHEMBL17315503 | 0.82 | PRSS1 (0.48) | SMN1; SMN2ALDH1A1MAPK1HSD17B10L3MBTL1 | |
| SCHEMBL8953866 | 0.82 | PRSS1 (0.48) | SMN1; SMN2ALDH1A1MAPK1HSD17B10L3MBTL1 | |
| SCHEMBL14535153 | 0.82 | NPC1 (0.49) | SMN1; SMN2ALDH1A1MAPK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515947-B | SHP2 inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-115515947-A | SHP2 inhibitor and composition and application thereof | 贝达药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-9656956-B2 | Benzene, pyridine, and pyridazine derivatives | ESANEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150315555-A1 | Fragment Ligated Inhibitors Selective for the Polo Box Domain of PLK1 | UNIVERSITY OF SOUTH CAROLINA | 2015-11-05 | — | — | US | disclosed |
| US-9175357-B2 | Fragment ligated inhibitors selective for the polo box domain of PLK1 | UNIVERSITY OF SOUTH CAROLINA (US) | 2015-11-03 | — | — | US | disclosed |
| US-20120202970-A1 | Fragment Ligated Inhibitors Selective for the Polo Box Domain of PLK1 | UNIVERSITY OF SOUTH CAROLINA (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2010015668-A1 | CONJUGATED PROTEINS WITH PROLONGED IN VIVO EFFICACY | NOVO NORDISK A/S (DK) | 2010-02-11 | — | — | WO | disclosed |
| EP-0255415-A2 | Use of phenylethanolamines for the preparation of medicaments acting on gastrointestinal troubles | ELF SANOFI (FR) | 1988-02-03 | — | — | EP | disclosed |
| EP-0047536-B1 | SUBSTITUTED PROPYLAMINES | ELI LILLY AND COMPANY (US) | 1984-06-27 | — | — | EP | disclosed |
| EP-0047536-A2 | Substituted propylamines | ELI LILLY AND COMPANY (US) | 1982-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315555-A1 | Fragment Ligated Inhibitors Selective for the Polo Box Domain of PLK1 | PLK1, POLD1, CTDSP1 | SMN1; SMN2 3270/4885ALDH1A1 4672/4885MAPK1 1804/4885 |
| US-20120202970-A1 | Fragment Ligated Inhibitors Selective for the Polo Box Domain of PLK1 | PLK1, POLD1, CTDSP1 | SMN1; SMN2 3270/4885ALDH1A1 4672/4885MAPK1 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.